X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement equity awards to new employees effective July 31, 2026 under its 2019 Inducement Equity Incentive Plan.

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement equity awards to new employees effective July 31, 2026 under its 2019 Inducement Equity Incentive Plan. The awards comprise stock options to purchase an aggregate of 12,000 shares of common stock, granted pursuant to Nasdaq Listing Rule 5635(c)(4) and approved by the Compensation Committee.

The options have a ten-year term and an exercise price of $3.98 per share, equal to X4’s closing stock price on July 31, 2026. Each option vests over four years, with 25% vesting after 12 months and the remainder vesting monthly over 36 months, subject to continued employment and the terms of the 2019 Inducement Plan and related award agreements. X4 focuses on rare hematology diseases and has developed mavorixafor, approved as XOLREMDI for WHIM syndrome, and is running the global Phase 3 4WARD trial in chronic neutropenic disorders.

Argus Aug 4 session 12 alerts

+4.89% close to close 0.5x rel. volume Open Argus

Details

Market reaction after employee inducement grants: XFOR +4.89% in the Aug 4 session

$408.40M Market Cap

In the Aug 4 session, XFOR gained 4.89%, reflecting a moderate positive market reaction. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The prior inducement-grant disclosure, news_id 1079043, recorded a 0.51% 24-hour reaction. That comp...

Analysis

The prior inducement-grant disclosure, news_id 1079043, recorded a 0.51% 24-hour reaction. That comparable precedent adds context, while the active S-3 shelf and recent net-selling insider record warrant monitoring.

Key Figures

Options granted: 12,000 shares Exercise price: $3.98 per share Option term: 10 years +4 more

Options granted

12,000 shares

Inducement awards effective July 31, 2026

Exercise price

$3.98 per share

Equal to the July 31, 2026 closing price

Option term

10 years

Term of each inducement option

Vesting period

4 years

Employee option vesting schedule

Initial vesting

25%

Shares vesting after 12 months

Initial vesting date

12 months

After grant date, subject to continued employment

Remaining vesting

36 months

Monthly vesting after the initial 12 months

Historical Context

5 past events · Latest: Jul 07

5 events

1. Jul 07

   Inducement grants

   24h Move

   +0.5%

   Stock options granted to new employees under the inducement equity plan.

2. Jul 01

   Board appointment

   24h Move

   -12.5%

   Kelly Gold joined the board as an independent director and Audit Committee member.

3. Jun 01

   Inducement grants

   24h Move

   -1.7%

   Inducement options covered 160,000 shares at a $4.31 exercise price.

4. May 27

   Conference presentation

   24h Move

   +0.8%

   Management scheduled a presentation at the Jefferies Global Healthcare Conference.

5. May 06

   Q1 earnings

   24h Move

   +4.3%

   EU authorization, trial progress, and cash runway were disclosed with quarterly results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), cxcr4 antagonist, phase 3 clinical trial, fast track designation

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

cxcr4 antagonist medical

"mavorixafor, an orally available CXCR4 antagonist"

A CXCR4 antagonist is a medicine that blocks a specific cell surface receptor called CXCR4, stopping signals that guide cell movement and survival. Think of it like putting a padlock on a door that cancer cells or immune cells use to travel and hide; this can slow tumor spread, help release stem cells for transplant, or interfere with viruses. For investors, drugs using this mechanism can create clear clinical milestones, niche market opportunities, and regulatory risks tied to trial results.

phase 3 clinical trial medical

"conducting a global, pivotal Phase 3 clinical trial"

A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.

fast track designation regulatory

"FDA has granted Fast Track designation to mavorixafor"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 12,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $3.98 per share, which is equal to the closing price of X4’s common stock on July 31, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did X4 Pharmaceuticals (XFOR) announce on July 31, 2026?

X4 Pharmaceuticals granted stock options for an aggregate of 12,000 common shares to new employees. According to X4 Pharmaceuticals, these inducement awards were issued under the 2019 Inducement Equity Incentive Plan as a material incentive for individuals not previously employed by the company.

What are the vesting terms of the new X4 Pharmaceuticals (XFOR) inducement stock options?

The inducement options vest over four years with a one-year cliff before monthly vesting. According to X4 Pharmaceuticals, 25% vests after 12 months, and the remaining 75% vests monthly over the next 36 months, subject to continued employment with the company.

What is the exercise price and term of the new X4 Pharmaceuticals (XFOR) inducement options?

The inducement options have an exercise price of $3.98 per share and a ten-year term. According to X4 Pharmaceuticals, the exercise price equals the closing price of its common stock on July 31, 2026, when the awards became effective.

Why did X4 Pharmaceuticals (XFOR) use Nasdaq Listing Rule 5635(c)(4) for these inducement awards?

X4 used Nasdaq Listing Rule 5635(c)(4) to grant equity awards as a material inducement for new hires. According to X4 Pharmaceuticals, the 2019 Inducement Plan is used exclusively for individuals who were not previously employees of the company.

How do the 2026 inducement grants fit into X4 Pharmaceuticals’ (XFOR) 2019 Inducement Equity Incentive Plan?

The 12,000-share option grants are issued under X4’s 2019 Inducement Equity Incentive Plan for new employees. According to X4 Pharmaceuticals, all options are subject to the plan’s terms and individual award agreements governing vesting, exercise, and other conditions.

What therapies is X4 Pharmaceuticals (XFOR) developing alongside announcing these inducement grants?

X4 is developing and commercializing therapies for rare hematology diseases, including mavorixafor. According to X4 Pharmaceuticals, mavorixafor is approved as XOLREMDI for WHIM syndrome and is being evaluated in the global Phase 3 4WARD trial for chronic neutropenic disorders.